Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Maternal use of narcotics may place their infants at risk for neurodevelopment delay. We hypothesized that exposure to daily, high dose methadone may pose an increased risk of an abnormal neurodevelopmental outcome in early infancy. Fifteen infants of mothers enrolled in a Methadone program have been enrolled to date in a study examining the effects of in utero methadone exposure on infant growth and neurodevelopmental outcome. Mean maternal methadone dose prior to delivery was 93±42 mg/day. The infants were matched for maternal age, Hollingshead SES score, birth weight and gestation with 15 infants with no history of in utero drug exposure. A third group of infants with in utero exposure to illicit narcotics, cocaine or both were also evaluated (n=12). Initial assessment at mean corrected age 2.5 mos included anthropometric measurements, complete neurological exam and developmental testing using the Alberta Infant Motor Scale (AIMS) and the Bayley Scales of Infant Development. Results are shown: (Table)
Bier, JA., Ferguson, A., Grenon, D. et al. Outcome of Infants Born to Mothers Treated with Methadone during Pregnancy.
Pediatr Res45, 120 (1999). https://doi.org/10.1203/00006450-199904020-00712